Table 1 Demographics of HSCT donors and recipients in the discovery and validation cohorts
| Â | Discovery cohort | Validation cohort | ||
|---|---|---|---|---|
(n = 85 pairs) | (n = 32 pairs) | |||
| Â | Donors | Recipients | Donors | Recipients |
Sex | Â | Â | Â | Â |
 Female | 41 | 27 | 14 | 7 |
 Male | 44 | 58 | 18 | 25 |
Age at transplant (years) | Â | Â | Â | Â |
 Median | 48 | 52 | 53 | 55 |
 Range | 14–72 | 21–66 | 22–71 | 23–64 |
CMV serostatus | Â | Â | Â | Â |
 Positive | 38 | 43 | 14 | 11 |
 Negative | 31 | 32 | 16 | 21 |
 NA | 16 | 10 | 2 | 0 |
Max. acute GVHD | Â | Â | Â | Â |
 Absent | – | 39 | – | 15 |
 Grade I ('mild') | – | 24 | – | 3 |
 Grade II ('mild') | – | 13 | – | 5 |
 Grade III ('severe') | – | 8 | – | 7 |
 Grade IV ('severe') | – | 1 | – | 2 |
Max. chronic GVHD | Â | Â | Â | Â |
 Absent | – | 54 | – | 2 |
 Limited | – | 21 | – | 10 |
 Extensive | – | 9 | – | 3 |
 NA | – | 1 | – | 17 |
Diagnosis | Â | Â | Â | Â |
 Acute lymphoblastic leukemia | – | 1 | – | 1 |
 Acute myeloid leukemia | – | 17 | – | 8 |
 Chronic granulomatous disease | – | 1 | – | 0 |
 Chronic lymphocytic leukemia (CLL) | – | 11 | – | 0 |
 Chronic myeloid leukemia (CML) | – | 0 | – | 3 |
 Chronic myelomonocytic leukemia | – | 1 | – | 0 |
 Hodgkin lymphoma | – | 9 | – | 4 |
 Myelodysplasia (MDS) | – | 2 | – | 0 |
 MDS/CML/CLL | – | 1 | – | 0 |
 Myelofibrosis | – | 0 | – | 2 |
 Myeloproliferative syndromes/MDS | – | 0 | – | 2 |
 Myeloma | – | 3 | – | 0 |
 Non-Hodgkin lymphoma | – | 37 | – | 8 |
 Other | – | 0 | – | 4 |
 NA | – | 2 | – | 0 |
| Â | Sibling pairs | Sibling pairs | ||
Sex match (donor/recipient) | Â | Â | ||
 Male/male | 30 | 14 | ||
 Female/female | 13 | 3 | ||
 Male/female | 14 | 4 | ||
 Female/male | 28 | 11 | ||
CMV match (donor/recipient) | Â | Â | ||
 Negative/negative | 18 | 13 | ||
 Positive/positive | 25 | 8 | ||
 Negative/positive | 13 | 3 | ||
 Positive/negative | 13 | 6 | ||
 NA | 16 | 2 | ||